Healthcare Testing Services Market Analysis & Forecast: 2026-2033

Healthcare Testing Services Market Size and Forecast – 2026 to 2033

The Healthcare Testing Services Market is anticipated to grow at a CAGR of 6.2% with USD 12.2 Bn share in 2026 and is expected to reach USD 20.7 Bn in 2033. Rising chronic diseases drive the Healthcare Testing Services Market, while healthcare providers and patients demand early and accurate diagnostics. Approximately 60% of Americans have at least one chronic disease, contributing substantially to healthcare costs and economic burden.

Key Takeaways

• Chemical Testing holds the largest market share of 38.8% in 2026, owing to growth in pharmaceutical and biopharmaceutical R&D. The U.S. pharmaceutical industry invested approximately USD 96 Bn in R&D in 2023, while biopharmaceutical companies continue to increase spending on drug development and quality assurance activities, driving demand for chemical characterization, impurity profiling, and stability testing.
• Anti-viral Drugs are expected to hold the largest market share of 32.7% in 2026, owing to the rising burden of viral diseases. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 2.4 million people in the U.S. are living with hepatitis C, while approximately 1.2 million people are living with HIV, sustaining demand for antiviral drug development, manufacturing, and testing services.
• Preclinical acquired the largest market share of 43.3% in 2026, owing to the expansion of drug discovery pipelines. According to industry reports, more than 9,000 drugs are currently in various stages of clinical and preclinical development globally, with a significant proportion in early-stage research, increasing the need for toxicology, bioanalytical, and safety testing services before human trials.
• The Pharmaceutical Industry captures the largest market share of 39.9% in 2026, owing to rising global drug demand. Global pharmaceutical sales are projected to exceed USD 1.7 trillion by 2030, while prescription drug spending in the U.S. surpassed USD 450 Bn annually, driving extensive requirements for analytical, microbiological, and regulatory testing services throughout the product lifecycle.
• North America is expected to acquire the dominant share of 41.1% in 2026 owing to the strong pharmaceutical & biotech industry presence.

Current Events and Their Impact on the Healthcare Testing Services Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Preclinical acquired the largest market share

Preclinical acquired the largest market share of 43.3% in 2026 owing to the growth of biologics & advanced therapies. Growing drug discovery activity and rising investment in pharmaceutical research drive the expansion of preclinical services in the Healthcare Testing Services Market. Companies perform extensive safety, toxicity, and pharmacology studies to evaluate drug candidates before clinical trials begin. Developers advance biologics, gene therapies, and other innovative treatments, which increases demand for specialized testing. Regulatory bodies like the U.S. Food and Drug Administration enforce strict requirements, while organizations increasingly outsource work to contract research organizations, strengthening the need for efficient and reliable preclinical testing services. For instance, in April 2026, Amazon Web Services has launched Amazon Bio Discovery, an AI-powered drug discovery tool that helps researchers design and test new drugs. The agentic AI application aims to accelerate preclinical drug discovery and bring antibody therapies to patients more quickly.

Why is Chemical Testing Acquiring the Largest Market Share?

Chemical Testing hold the largest market share of 38.8% in 2026. Stringent regulations from agencies like the U.S. Food and Drug Administration and European Medicines Agency drive chemical testing in the Healthcare Testing Services Market by enforcing drug safety and quality standards. Pharmaceutical and biologics companies expand development pipelines, increase focus on impurity detection, and scale generic drug production, which boosts demand. Companies adopt advanced analytical technologies and manage global supply chains that require consistent compliance testing, while growing concerns about contamination and product recalls push organizations to prioritize comprehensive chemical analysis throughout the product lifecycle. In September 2025, Youth Affairs and Sports Minister Dr. Mansukh Mandaviya stressed the need for advanced anti-doping research and launched an indigenous Chemical Reference Material for Anti-Doping Analysis at the 22nd Governing Body Meeting of the National Dope Testing Laboratory (NDTL) in New Delhi.

Anti-viral Drugs expected to hold largest market share

Anti-viral Drugs expected to hold largest market share of 32.7% in 2026 owing to the complex drug development & novel therapies. Rising cases of viral diseases such as HIV/AIDS, hepatitis B, and COVID-19 drive the growth of antiviral drugs in the Healthcare Testing Services Market. In 2024, approximately 41 million people worldwide were living with HIV, including 1.4 million children under 15 years of age, with more than half of all cases concentrated in Eastern and Southern Africa. Pharmaceutical companies strengthen pandemic preparedness, accelerate drug development, and fast-track regulatory approvals, which increases testing demand. They address emerging drug-resistant viral strains and expand clinical trials that require continuous monitoring. Advances in diagnostics and global manufacturing further push organizations to rely on robust and reliable testing services. In June 2026, Qubigen launched a collaborative project with the German Center for Infection Research (DZIF) and the Japanese Institute of Microbial Chemistry (IMC) to develop antiviral small-molecule drugs using decentralized AI-driven design, targeting emerging infectious diseases.

Which End User segment dominates the market? 

To learn more about this report, Request Free Sample

Pharmaceutical Industry captures the largest market share of 39.9% in 2026. The pharmaceutical industry drives the Healthcare Testing Services Market as companies increase drug development activity and strengthen quality assurance across production stages. They actively perform extensive analytical, bioanalytical, and clinical testing to ensure safety, efficacy, and regulatory compliance. Growth in biologics, biosimilars, and generic drugs further raises testing requirements. Regulatory authorities such as the U.S. Food and Drug Administration and European Medicines Agency enforce strict standards, while companies outsource work to contract research organizations to improve efficiency and access advanced testing capabilities.

Healthcare Testing Services Market Trends

• Growing outsourcing of testing activities to Contract Research Organizations (CROs) is expanding access to specialized expertise while reducing operational costs. Industry estimates suggest that over 50% of clinical development activities are outsourced, reflecting the increasing reliance on external testing providers.
• Expanding biologics, biosimilars, and cell and gene therapy development is increasing demand for specialized testing services. Biologics account for approximately 40% of the global pharmaceutical pipeline, requiring extensive analytical and bioanalytical testing throughout development and commercialization.
• Rising prevalence of chronic and infectious diseases such as cancer, diabetes, and HIV/AIDS continues to drive testing demand. In 2024, approximately 41 million people worldwide were living with HIV, while cancer accounted for nearly 20 million new cases annually, creating sustained demand for diagnostic and clinical testing services.

Regional Insights 

To learn more about this report, Request Free Sample

North America dominates owing to focus on drug safety & post-market surveillance

North America is expected to acquire the dominant share of 41.1% in 2026. Strong pharmaceutical and biotechnology activity in the United States drives the Healthcare Testing Services Market in North America. Companies actively conduct extensive drug development and clinical research, which increases demand for testing services. Regulatory agencies such as the U.S. Food and Drug Administration and Health Canada enforce strict compliance standards and require continuous testing. High healthcare spending, advanced research infrastructure, and rapid adoption of innovative technologies further strengthen market growth, while companies increasingly outsource work to contract research organizations to improve efficiency and service quality. In February 2026, Quest Diagnostics introduced Quest Flow Cytometry MRD for Myeloma, a new blood test that uses advanced flow cytometry to detect measurable residual disease in multiple myeloma patients. The test offers sensitivity comparable to next-generation sequencing at a lower cost, supporting improved patient care and outcomes.

Asia Pacific Healthcare Testing Services Market Trends

Rising cases of chronic diseases and a growing elderly population drive demand for healthcare testing services across Asia Pacific. Healthcare providers expand infrastructure and adopt advanced diagnostic technologies, while governments support improved screening and early detection programs. People increasingly seek preventive care due to higher health awareness and rising medical spending. Private diagnostic companies expand networks, and laboratories outsource services more widely, strengthening market growth across emerging economies in the region. For instance, in March 2026, MY LYF CARE has launched a centralized diagnostic laboratory in Greater Noida to expand technology-enabled healthcare access in India. The facility strengthens its diagnostic capabilities and supports its network of Smart Pharmacy centres and franchise partners.

United States Healthcare Testing Services Market Trends

Key drivers of the United States healthcare testing services market include the growing aging population and the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, which drive higher demand for diagnostic testing. Healthcare systems increasingly adopt preventive screening programs. Companies advance molecular diagnostics and automation while expanding point-of-care testing. Post-pandemic awareness encourages testing. Policymakers support the sector through reimbursement frameworks and strict regulations. The shift toward personalized medicine further increases demand for accurate, timely laboratory testing services across healthcare providers. For instance, in February 2026, NeoGenomics has launched PanTracer Pro, a diagnostic solution for advanced-stage solid tumor care that integrates comprehensive genomic profiling with customized testing in a single order, enabling faster turnaround times.

Japan Healthcare Testing Services Market Trends

Japan’s healthcare testing services market grows as a rapidly aging population drives higher demand for diagnostic and preventive care services. Increasing cases of chronic conditions such as diabetes and cardiovascular diseases further fuel the need for frequent testing. Healthcare providers adopt advanced technologies like laboratory automation, AI-based diagnostics, and molecular testing to improve accuracy and efficiency. Government initiatives promote early disease detection, while expanding health insurance access and rising awareness of preventive healthcare strengthen demand. Ongoing innovation in genomics and personalized medicine also supports market expansion.

Who are the Major Companies in Healthcare Testing Services Industry

Some of the major key players in Healthcare Testing Services are Eurofins Scientific, PPD, Inc., Microbac Laboratories, Inc., ARL Bio Pharma, Inc., Consumer Product Testing Company, Inc., Element Materials Technology Ltd., Intertek Group plc, DYNALABS LLC., ADPEN Laboratories, Inc., Moderna Inc., ZYUS Life Sciences Inc., PCI Pharma Services,  Perfectus Biomed, Alcami Corporation Inc., SGS SA, Predictive Laboratories, Lasa Supergenerics Ltd, Roche Diagnostics India, National Jewish Health, Pfizer Inc. and Parexel International Corporation.

Key News

• In May 2026, Abingdon Health has highlighted its customer UpFront Diagnostics’ UK launch of LVOne, the first rapid blood test for stroke detection at the point of care, following UKCA approval and rollout with the London Ambulance Service.

Market Report Scope 

Analyst Opinion

• Healthcare Testing Services are not expanding due to cyclical healthcare trends but because of a structural rise in diagnostic dependency across populations. Globally, an estimated 1 in 3 clinical decisions now relies directly on laboratory testing, underscoring how testing has shifted from a support function to a core pillar of modern medicine. In chronic disease management alone, patients with conditions such as diabetes and cardiovascular disorders often require repeated biomarker and pathology testing throughout the year, reinforcing sustained demand rather than episodic usage.
• At a system level, diagnostic intensity is increasing as aging populations require continuous screening; for instance, individuals over 65 typically undergo significantly higher annual test volumes compared to younger cohorts due to multimorbidity risk. In Japan, where more than 1 in 10 people are already aged 80 or above, this dynamic is particularly pronounced, creating persistent demand pressure on laboratory networks and hospital-based diagnostics.
• Technological advancements are also reshaping throughput and accuracy expectations. High-throughput automated analyzers in modern laboratories can process thousands of samples per hour, while AI-assisted pathology systems are reducing error rates in areas like oncology screening. This is not incremental improvement—it is fundamentally expanding testing accessibility and enabling earlier disease detection at scale.
• Additionally, molecular diagnostics is moving from niche to routine use, with infectious disease panels and genetic testing increasingly integrated into standard care pathways. The result is a market driven less by discretionary healthcare spending and more by unavoidable clinical necessity, where every expansion in screening guidelines or diagnostic precision directly translates into higher testing volumes.

Market Segmentation

• By Service Type (Revenue, USD Bn, 2021-2033)
  • Chemical Testing
  • Microbiological Testing
  • Toxicology Testing
  • Stability Testing
  • Others
• By Product Type (Revenue, USD Bn, 2021-2033)
  • Anti-viral Drugs
  • HIV Drugs
  • Fertility Drugs
  • Anti-diabetic Drugs
  • Respiratory Drugs
  • Anticoagulants
  • Medical Devices
  • Pharmaceutical Packaging
  • Others
• By Development Stage (Revenue, USD Bn, 2021-2033)
  • Preclinical
  • Clinical
  • Manufacturing
• By End User (Revenue, USD Bn, 2021-2033)
  • Pharmaceutical Industry
  • Contract Research Organization
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research interviews

• Interviews with hospital laboratory directors and clinical pathologists across tertiary care hospitals
• Discussions with diagnostic service providers and independent pathology lab chains
• Inputs from medical device specialists focusing on in-vitro diagnostics and automation systems

Databases

• National health statistics repositories and disease surveillance databases
• WHO Global Health Observatory dataset
• OECD Health Statistics database
• PubMed and clinical trial registries for diagnostic performance data

Magazines

• Nature Medicine (diagnostic and translational research updates)
• The Lancet Digital Health (AI diagnostics and lab innovation insights)
• Clinical Laboratory News
• Biomedical Science & Technology publications

Journals

• Journal of Clinical Laboratory Analysis
• Clinical Chemistry
• American Journal of Clinical Pathology
• Diagnostics (MDPI) peer-reviewed journal

Newspapers

• The Japan Times (healthcare system and aging population coverage)
• Nikkei Asia (health infrastructure and medical technology developments)
• Financial Times (global healthcare innovation reporting)
• The Guardian (public health and diagnostic accessibility reporting)

Associations

• World Health Organization (WHO)
• International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
• American Association for Clinical Chemistry (AACC)
• Japan Association of Clinical Laboratory Systems

Public Domain sources

• Government health ministry publications and policy reports
• National census and demographic reports
• Hospital and public health institution annual reports
• Open-access clinical guidelines and screening protocol documents

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years